Editorial
An innovative mesothelioma treatment based on miR-16 mimic loaded EGFR targeted minicells (TargomiRs)
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S1-S4
.
(11 February 2018)
Treatment redirection from cure to palliation, then cure again? A cautious, but urgent matter
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S5-S8
.
(11 February 2018)
Emerging resistance pathways in lung cancer: what has ROS-1 taught us?
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S9-S12
.
(11 February 2018)
Targeting the metastatic niche through anti-angiogenic approaches in epidermal growth factor receptor mutant non-small cell lung cancer
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S13-S18
.
(11 February 2018)
PACIFIC trial: new perspectives for immunotherapy in lung cancer
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S19-S24
.
(11 February 2018)
Can population data guide surveillance strategies for second primary lung cancers?
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S25-S27
.
(11 February 2018)
Nivolumab as first-line treatment in non-small cell lung cancer patients—key factors: tumor mutation burden and PD-L1 ≥50%
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S28-S30
.
(11 February 2018)
Next-generation molecular therapy in lung cancer
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S31-S34
.
(11 February 2018)
Putting the brakes on CTLA-4 inhibition in lung cancer?
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S35-S38
.
(11 February 2018)
Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?—the shifting paradigm of therapeutics
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S39-S45
.
(11 February 2018)
Tumor heterogenicity: multiple needle biopsies from different lesion sites—key to successful targeted therapy and immunotherapy
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S46-S48
.
(11 February 2018)
Long-term CT surveillance after primary lung cancer treatment captures events in all risk groups
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S49-S53
.
(11 February 2018)
The risk of second primary lung cancer: an unsolved dilemma
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S54-S56
.
(11 February 2018)
Editorial on PanCan study
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S57-S59
.
(11 February 2018)
Letter to the Editor
Response to “an innovative mesothelioma treatment based on mir-16 mimic loaded EGFR targeted minicells (TargomiRs)”
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S60-S61
.
(11 February 2018)
Meet the Professor
Prof. Lukas Bubendorf: the pros and cons of using cytology specimens in molecular testing
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S62-S63
.
(11 February 2018)
Prof. Nir Peled: CT first, biomarkers next
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S64-S66
.
(11 February 2018)
Dr. Lucio Crinò: our greatest challenge is finding the right treatment for the right patients
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S67-S69
.
(11 February 2018)
Dr. David Ross Camidge: always be the first to see something
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S70-S71
.
(11 February 2018)
Dr. Jhingook Kim: surgeons are not merely technicians, but scientists
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S72-S73
.
(11 February 2018)
Dr. Vera Hirsh: improving patient’s quality of life is necessary for cancer treatment
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S74-S75
.
(11 February 2018)
Dr. Ignacio Gil-Bazo: family support is my key to success!
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S76-S77
.
(11 February 2018)
Professor Fred R. Hirsch, the IASLC CEO—showing you around the 18th World Conference on Lung Cancer (WCLC 2017)
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S78-S80
.
(11 February 2018)
Professor David Ball: prophylactic cranial irradiation (PCI) benefits patients with SCLC
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S81-S82
.
(11 February 2018)
Professor Raymond U. Osarogiagbon: another major challenge over next decades—how to incorporate the cutting-edge diagnostics and biologic prognosticating ability into a traditionally anatomy-centered TNM staging system
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S83-S87
.
(11 February 2018)
Professor Fred R. Hirsch: together, our voices are much stronger than individually—a special interview about the 2017 Lung Cancer Awareness Month campaign
Translational Lung Cancer Research
2018;
7
(Suppl 1)
:S88-S90
.
(11 February 2018)
Disclosure:
The supplement was published without any sponsorship or funding.
